Nkarta, Inc (NKTX)

Etorro trading 970x250

About Nkarta, Inc

Nkarta, Inc., a biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company’s approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its co-lead product candidates are NKX101, a pre-clinical product that enhances the power of innate NK biology to detect and kill cancerous cells; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded in 2015 and is headquartered in South San Francisco, California. Address: 6000 Shoreline Court, South San Francisco, CA, United States, 94080

Nkarta, Inc News and around…

Latest news about Nkarta, Inc (NKTX) common stock and company :

61 Biggest Movers From Yesterday
02 Dec, 2021 FinancialContent

Gainers Arbutus Biopharma Corporation (NASDAQ: ABUS) shares jumped 44.1% to close $4.61 on above-average volume on Wednesday. The ...

Sum Up The Pieces: BIB Could Be Worth $114
30 Nov, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the ProShares ProShares Ultra Nasdaq Biotechnology ETF (BIB), we found that the implied analyst target price for the ETF based upon its underlying holdings is $113.61 per unit.

15 Pharmaceutical Stocks to Buy According to Peter Kolchinsky’s RA Capital
25 Nov, 2021 Yahoo! Finance

In this piece, we will take a look at the top 15 pharmaceutical stocks to buy according to Peter Kolchinsky’s RA Capital. If you want to skip our introduction and take a look at the top five stocks in this list, head on over to 5 Pharmaceutical Stocks to Buy According to Peter Kolchinsky’s RA […]

Can Nkarta (NKTX) Climb 270% to Reach the Level Wall Street Analysts Expect?
15 Nov, 2021 Yahoo! Finance

The mean of analysts' price targets for Nkarta (NKTX) points to a 270.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Nkarta Presents New Preclinical Data from Engineered NK Cell Platform at SITC 36th Annual Meeting
12 Nov, 2021 Yahoo! Finance

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced the presentation of four preclinical data abstracts focused on its natural killer cell platform and pipeline at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting and Pre-Conference Programs. "The data we presented at this year's SITC meeting showcase the rapid and continuo

Oversold Conditions For Nkarta (NKTX)
10 Nov, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

Nkarta Reports Third Quarter 2021 Financial Results and Business Update
10 Nov, 2021 Yahoo! Finance

Initial data expected in 1H 2022 from Phase 1 clinical trial of NKX101 in AML and MDSSuccessful dosing of NKX019 in patients with B cell malignancies; initial Phase 1 clinical trial data expected in 2022 SOUTH SAN FRANCISCO, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today reported financial results for the third quarter ended September 30, 2021. “We are on track to a

Nkarta to Participate at Upcoming Investor Conferences
04 Nov, 2021 Yahoo! Finance

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at these upcoming investor conferences: Cowen 5th Annual IO Next SummitNovember 15, 202111:15 a.m. ET - fireside chat presentation Stifel 2021 Virtual Healthcare ConferenceNovember 17, 20212:00 p.m. ET – fireside chat presentation Evercore ISI 4th Annual HealthCONx Confer

Analysts Predict 16% Gains Ahead For VBK
29 Oct, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Small-Cap Growth ETF (VBK), we found that the implied analyst target price for the ETF based upon its underlying holdings is $343.47 per unit.

35 Biggest Movers From Friday
11 Oct, 2021 FinancialContent

Gainers ChemoCentryx, Inc. (NASDAQ: CCXI) shares surged 96% to close at $38.41 on Friday. The FDA approved ChemoCentryx’s ...

28 Stocks Moving In Friday's Mid-Day Session
08 Oct, 2021 FinancialContent

Gainers ChemoCentryx, Inc. (NASDAQ: CCXI) shares climbed 60.8% to $31.51. The FDA approved ChemoCentryx’s Tavneos (avacopan) ...

Nkarta Expects Initial Data From CAR NK Cell Therapy In Blood Cancer In 2022
08 Oct, 2021 FinancialContent

Nkarta Inc(NASDAQ: NKTX) hasupdated guidance on initial data readoutof Phase 1 trial of NKX101 in relapsed or ...

The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
08 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Nkarta Announces Updates to NKX019 and NKX101 Clinical Development Programs
07 Oct, 2021 Yahoo! Finance

First patients dosed in Phase 1 clinical trial evaluating NKX019 in CD19+ advanced B cell malignanciesInitial data from the NKX019 clinical trial expected in 2022Initial data from Phase 1 clinical trial evaluating NKX101 in AML and MDS expected in 1H 2022 SOUTH SAN FRANCISCO, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced NKX019 and NKX101 clinical develop

Here's Why We're Not Too Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Situation
07 Oct, 2021 Yahoo! Finance

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Nkarta is Now Oversold (NKTX)
06 Oct, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

Nkarta to Present Preclinical Data from Engineered NK Cell Platform at SITC 36th Annual Meeting
01 Oct, 2021 Yahoo! Finance

Data support potential clinical applications of CRISPR/Cas9 genome engineering, CD70 chimeric antigen receptor (CAR) targeting, and donor selection algorithms in next generation NK cell development programs Update also highlights novel methods for scaling the expansion of engineered NK cells to potentially supply a life cycle’s worth of commercial product from a single donor SOUTH SAN FRANCISCO, Calif., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company de

Implied VBK Analyst Target Price: $336
27 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Small-Cap Growth ETF (VBK), we found that the implied analyst target price for the ETF based upon its underlying holdings is $336.47 per unit.

Nkarta to Participate at Upcoming Investor Conference
14 Sep, 2021 FinancialContent
53 Biggest Movers From Friday
07 Sep, 2021 FinancialContent

Gainers Innate Pharma S.A. (NASDAQ: IPHA) shares surged 47.1% to settle at $6.15 on Friday after SVB Leerink upgraded the stock ...

Nkarta Reports Second Quarter 2021 Financial Results and Business Progress
12 Aug, 2021 FinancialContent
3 Things About CRISPR Therapeutics That Smart Investors Know
23 Jul, 2021 FinancialContent

The company is on track to be the first to market with a gene-editing therapy for blood disorders.

Benzinga's Top Ratings Upgrades, Downgrades For July 16, 2021
16 Jul, 2021 FinancialContent

Upgrades According to Citigroup, the prior rating for Alcoa Corp (NYSE:AA) was changed from Neutral to Buy. In the ...

12 Health Care Stocks Moving In Thursday's Intraday Session
15 Jul, 2021 FinancialContent

Gainers Nkarta (NASDAQ:NKTX) shares moved upwards by 8.03% to $30.0 during Thursday's regular session. The current ...

Nkarta Unveils Plans For New San Francisco HQ, Manufacturing Site
14 Jul, 2021 FinancialContent

Nkarta Therapeutics Inc(NASDAQ: NKTX)will be moving into an 88,000-square-foot facilitythat will not only serve as ...

Nkarta Establishes New Combined NK Cell Therapy Manufacturing Facility / Company Headquarters
14 Jul, 2021 FinancialContent
Analysts Predict 11% Upside For The Holdings of PBSM
16 Jun, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco PureBeta MSCI USA Small Cap ETF (PBSM), we found that the implied analyst target price for the ETF based upon its underlying holdings is $44.04 per unit.

Nkarta to Present at Upcoming Investor Conference
16 Jun, 2021 FinancialContent
Nkarta Therapeutics CEO, Paul Hastings, Named BIO Chair for 2021-2022 Term
14 Jun, 2021 FinancialContent
How Much Will the Nkarta Deal Help CRISPR Therapeutics?
06 Jun, 2021 FinancialContent

Unfortunately, this isn't an endorsement by a big drug developer.

Nkarta, Inc (NKTX) is a NASDAQ Common Stock listed in , ,

970x250